These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 9610734)

  • 21. A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts.
    Buchsbaum DJ; ten Haken RK; Heidorn DB; Lawrence TS; Glatfelter AA; Terry VH; Guilbault DM; Steplewski Z; Lichter AS
    Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1033-41. PubMed ID: 2347713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
    Stein R; Chen S; Haim S; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2636-41. PubMed ID: 9406718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
    Govindan SV; Stein R; Qu Z; Chen S; Andrews P; Ma H; Hansen HJ; Griffiths GL; Horak ID; Goldenberg DM
    Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
    Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
    J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine.
    Stein R; Govindan SV; Chen S; Reed L; Spiegelman H; Griffiths GL; Hansen HJ; Goldenberg DM
    Crit Rev Oncol Hematol; 2001; 39(1-2):173-80. PubMed ID: 11418314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
    Behr TM; Salib AL; Liersch T; Béhé M; Angerstein C; Blumenthal RD; Fayyazi A; Sharkey RM; Ringe B; Becker H; Wörmann B; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3232s-3242s. PubMed ID: 10541369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
    Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
    Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):813-23. PubMed ID: 9240651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
    J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody.
    Andratschke M; Gildehaus FJ; Johannson V; Schmitt B; Mack B; Reisbach G; Lang S; Lindhofer H; Zeidler R; Wollenberg B; Luebbers CW
    Anticancer Res; 2007; 27(1A):431-6. PubMed ID: 17352264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis.
    DeNardo GL; DeNardo SJ; Wessels BW; Kukis DL; Miyao N; Yuan A
    Cancer Biother Radiopharm; 2000 Dec; 15(6):547-60. PubMed ID: 11190487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
    Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
    Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
    Colapinto EV; Zalutsky MR; Archer GE; Noska MA; Friedman HS; Carrel S; Bigner DD
    Cancer Res; 1990 Mar; 50(6):1822-7. PubMed ID: 2407345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R; Juweid M; Mattes MJ; Goldenberg DM
    Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1).
    Siler K; Eggensperger D; Hand PH; Milenic DE; Miller LS; Houchens DP; Hinkle G; Schlom J
    Biotechnol Ther; 1993; 4(3-4):163-81. PubMed ID: 8292968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
    Stein R; Goldenberg DM; Thorpe SR; Mattes MJ
    J Nucl Med; 1997 Mar; 38(3):391-5. PubMed ID: 9074526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
    Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ
    Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model.
    Buchegger F; Vacca A; Carrel S; Schreyer M; Mach JP
    Int J Cancer; 1988 Jan; 41(1):127-34. PubMed ID: 3335416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.